

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

June 14, 2001

(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
1036.2001-006

APPLICATION NO.  
09/738,625

APPLICANT  
Arnold Glazier

FILING DATE  
December 15, 2000

GROUP

U.S. PATENT DOCUMENTS

EXAM INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AU	Portoghese, P. S., "Bivalent Ligands and the Message - Address Concept in the Design of Selective Opioid Receptor Antagonists," <i>TIPS</i> , 10:230-235 (1989).
	AV	Crews, J.R., et al., "A Combination of Two Immunotoxins Exerts Synergistic Cytotoxic Activity Against Human Breast-Cancer Cell Lines," <i>Int. J. Cancer</i> , 51:772-779 (1992).
	AW	Chari, R.V.J., "Targeted Delivery of Chemotherapeutics: Tumor-activated Prodrug Therapy," <i>Advanced Drug Delivery Reviews</i> , 31:89-104 (1998).
	AX	Rihova, B. "Receptor-mediated Targeted Drug or Toxin Delivery," <i>Advanced Drug Delivery Reviews</i> , 29:273-289 (1998).
	AY	Calas, M., et al., "Antimalarial Activity of Compounds Interfering with Plasmodium falciparum Phospholipid Metabolism: Comparison Between Mono- and Bisquaternary Ammonium Salts," <i>J. Med. Chem.</i> , 43:505-516 (2000).
	AZ	Terskikh, A.V., et al., "'Peptabody': A New Type of High Avidity Binding Protein," <i>Proc. Natl. Acad. Sci.</i> 94:1663-1668 (1997).
	AR2	Kohler, J., et al., "Cross-reactive Trinitrophenylated Peptides as Antigens for Class II Major Histocompatibility Complex-restricted T Cells and Inducers of Contact Sensitivity in Mice. Limited T Cell Receptor Repertoire," <i>Eur J Immunol</i> 25:92-101 (1995).
↓	AS2	Sykulev, Y., et al., "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response," <i>Immunity</i> 4:565-571 (1996).

EXAMINER

/Karen A. Canella, Ph.D./

DATE CONSIDERED

07/24/2006

RECEIVED  
OCT 02 2001  
CH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

June 14, 2001

(See General sheets if necessary)

ATTORNEY DOCKET NO.  
1036.2001-006

APPLICATION NO.  
09/738,625

APPLICANT  
Arnold Glazier

FILING DATE  
December 15, 2000

GROUP

U.S. PATENT DOCUMENTS

EXAM- INER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
KAC	AR 5,849,718	12-15-98	Grosveld	514	44	
	AB 5,820,847	10-13-98	Low, et al.	424	9.1	
	AC 5,108,921	4-28-92	Low, et al.	435	240.1	
	AD 5,416,016	5-16-95	Low, et al.	435	240.1	
	AE 5,902,588	5-11-99	Greenwald, et al.	424	278.1	
	AF 5,556,609	9-17-96	Zamora	424	1.69	
	AG 5,567,408	10-22-96	Zamora	424	1.69	
	AH 4,975,278	12-4-90	Senter, et al.	424	94.3	
	AI 5,688,488	11-18-97	Low, et al.	424	1.69	
↓	AJ 5,914,312	6-22-99	Axworthy, et al.	514	8	
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	AL WO 99/53951	28.10.99	PCT	A61K	39/385	
	AM					
	AN					
	AO					
	AP					
	AQ					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AR	Asayama, S., et al., "Comb-Type Prepolymers Consisting of a Polyacrylamide Backbone and Poly(L-lysine) Graft Chains for Multivalent Ligands," <i>Bioconjugate Chem.</i> , 10:246-253 (1999).
KAC	AS	Costa, T., et al., "Receptor Binding and Biological Activity of Bivalent Enkephalins," <i>Biochemical Pharmacology</i> , 34(1):25-30 (1985).
KAC	AT	Portoghese, P.S., et al., "Opioid Agonist and Antagonist Bivalent Ligands as Receptor Probes," <i>Life Sciences</i> , 31:1283-1286 (1982).

EXAMINER

/Karen A. Canella, Ph.D./

DATE CONSIDERED

07/24/2006

RECEIVED  
OCT 02 2001  
H CENTER 1600/2900

644 164  
RECEIVED  
OCT 02 2001  
TECH CENTER 1600/2900  
P#14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Arnold Glazier

Application No.: 09/738,625

Group Art Unit: 1645

Filed: December 15, 2000

Examiner:

Title: SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES,  
MULTIFUNCTIONAL PRODRUGS, USE AS ANTINEOPLASTIC DRUGS



CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on	9/28/01
Date	Signature
Sandra D. Brigham	
Typed or printed name of person signing certificate	


INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or  
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):  
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.  
(Filed after payment of issue fee)



TECH CENTER 600/2900

OCT 02 2001

RECEIVED

Statement Under 37 CFR 1.57(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
  - ☐ the explanation provided in the Specification.
  - ☐ submission of the enclosed International Search Report.
  - ☐ the enclosed English language abstract.

☐ Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_\_  
Examiner

\_\_\_\_\_  
Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.


Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By

  
\_\_\_\_\_  
Steven G. Davis, Esq.  
Registration No.: 39,652  
Telephone: (781) 861-6240  
Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated:

September 28, 2001